Alnylam Pharmaceuticals Reports Fourth Quarter and 2008 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY): – Established Human Proof of Concept with an RNAi Therapeutic, a First for the Industry – – Advanced Pipeline with ALN-RSV and ALN-VSP Clinical Programs – – Continued Scientific Leadership, Consolidation of Leading Intellectual Property, and Formed Four Major Alliances in Last 12 Months with $175 Million in Realized Funding – – Ended 2008 with $513 Million in Cash and Earned $96 Million in Revenues, a Near Doubling of 2007 Revenues – – Net Loss Narrowed in 2008 as Compared to 2007 Due to Strong Revenues – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, reported its consolidated financial results for the fourth...

Want to see the full article?

• Purchase this article for only $3.00